- Home
- RXRX vs IMNM Comparison
RXRX vs IMNM Comparison
Compare RXRX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | IMNM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RXRX | IMNM |
|---|---|---|
| Price | $3.42 | $20.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $7.20 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 15.0M | 956.4K |
| Earning Date | 06-01-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.79 | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,681,000.00 | $6,941,000.00 |
| Revenue This Year | $16.50 | $18.41 |
| Revenue Next Year | $66.44 | $863.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.98 | $5.15 |
| 52 Week High | $7.18 | $27.65 |
Technical Indicators
Market Signals| Indicator | RXRX | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 39.24 |
| Support Level | $2.98 | $18.98 |
| Resistance Level | $5.12 | $22.57 |
| Average True Range (ATR) | 0.25 | 1.03 |
| MACD | 0.02 | -0.19 |
| Stochastic Oscillator | 39.09 | 20.45 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.